Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium (3-oxo-(17r)-17-28-norlup-20(29)-en)-2-oxoethyl-phosphonate
- Development stage
- Preclinical
- Lead developer
- Victor Babeș University of Medicine and Pharmacy Timișoara
- Modality
- Small Molecules
01
Overview
sodium (3-oxo-(17r)-17-28-norlup-20(29)-en)-2-oxoethyl-phosphonate is a semisynthetic pentacyclic triterpenoid derivative based on the betulonic acid (BoA) skeleton. It features a methylphosphonate moiety at the C17 position, which was designed to improve the pharmacokinetic and pharmacodynamic profile of natural triterpenoids like betulinic acid. In preclinical studies, the compound has demonstrated significant antimelanoma activity, specifically showing dose-dependent antiproliferative and anti-migratory effects against the B164A5 murine melanoma cell line. Mechanistically, it appears to induce apoptosis, as evidenced by nuclear condensation, while maintaining a favorable safety profile with low cytotoxicity to normal cells and no evidence of vascular disintegration in HET-CAM assays.
- Other names
- sodium betulonate phosphonateC17-phosphonate betulonic acid derivativeC-17-phosphonate betulonic acid derivativeC 17-phosphonate betulonic acid derivativesodium (3-oxolup-20(29)-en-28-oyl)oxymethylphosphonate
Beyond the preview
Go deeper on sodium (3-oxo-(17r)-17-28-norlup-20(29)-en)-2-oxoethyl-phosphonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium (3-oxo-(17r)-17-28-norlup-20(29)-en)-2-oxoethyl-phosphonate.